Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CARsgen CAR-T Approved to Start China Trials for Pancreatic Cancer

publication date: Apr 20, 2023

Shanghai CARsgen Therapeutics announced its CAR T-cell therapy that targets Claudin18.approved to start China trials as a postoperative adjuvant therapy for cCLDN18.2 positive pancreatic cancer (PC). CARsgen believes CT041 has the potential to be the first-in-class globally. The candidate targets CLDN18.2 positive solid tumors with a primary focus on gastric cancer/gastroesophageal junction cancer (GC/GEJ) and PC. CARsgen, a Shanghai-North Carolina company, focused on novel CAR T-cell therapies for hematologic malignancies and solid tumors. More details....

Stock Symbol: (HK: 2171)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital